Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

NCT01560663 is registered in ClinicalTrials.gov with Miguel Martín Jiménez as lead sponsor.

NCT NCT01560663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01560663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Lead sponsor
Miguel Martín Jiménez
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2012
Completion date
December 31, 2023
Enrollment
415 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer stage ii-iii